Entero Therapeutics, Inc.
Entero Therapeutics, Inc. (ENTO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
ento · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Entero Therapeutics, Inc. (ENTO) measures how much investors pay for each dollar of the company's trailing earnings. ENTO's current PE ratio of N/A is calculated by dividing its stock price of $2.85 by its TTM earnings per share of -$1.95.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2013 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Entero Therapeutics, Inc.You ENTO | $14M | N/A | — | -$1.95 |
 Allarity Therapeutics, Inc. ALLR | $25M | N/A | — | -$0.78 |
 Aspire Biopharma Holdings, Inc. ASBP | $1M | N/A | — | -$16.38 |
 Athira Pharma, Inc. ATHA | $27M | N/A | — | -$24.70 |
 BriaCell Therapeutics Corp. BCTX | $6M | N/A | — | -$19.37 |
 Cingulate Inc. CING | $25M | N/A | — | -$4.13 |
 Curis, Inc. CRIS | $6M | N/A | — | -$0.06 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-4.05 | — | |
2024-12-31 FY2024 | — | $-3.88 | — | |
2023-12-31 FY2023 | — | $-46.96 | — | |
2022-12-31 FY2022 | — | $-407.37 | — | |
2021-12-31 FY2021 | — | $-27544.98 | — | |
2020-12-31 FY2020 | — | $-48255.29 | — | |
2019-12-31 FY2019 | — | $-28425.72 | — | |
2018-12-31 FY2018 | — | $-36815.89 | — | |
2017-12-31 FY2017 | — | $-43847.52 | — | |
2016-12-31 FY2016 | — | $-94215.17 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Entero Therapeutics, Inc. (ENTO) measures how much investors pay for each dollar of the company's trailing earnings. ENTO's current PE ratio of N/A is calculated by dividing its stock price of $2.85 by its TTM earnings per share of -$1.95.
Frequently asked questions
ENTO pe ratio · 6 questionsENTO's current PE ratio is N/A as of 2026-06-08, based on a stock price of $2.85 and TTM EPS of -$1.95. Data sourced from Financial Modeling Prep via ENTO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Entero Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08